<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  

  
  
  
  
  
    
    
    
  
  

  <meta name="author" content="Shawn (Xiangyu) Pan">

  
  
  
    
  
  <meta name="description" content="Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a life-threatening hyperinflammatory syndrome triggered by EBV infection. It often becomes relapsed or refractory (r/r), given that etoposide-based regimens cannot effectively clear the virus. r/r EBV-HLH is invariably lethal in adults without allogeneic hematopoietic stem cell transplantation. Here, we performed a retrospective analysis of 7 r/r EBV-HLH patients who were treated with nivolumab on a compassionate-use basis at West China Hospital. All 7 patients tolerated the treatment and 6 responded to it. Five of them achieved and remained in clinical complete remission with a median follow-up of 16 months (range, 11.4-18.9 months). Importantly, both plasma and cellular EBV-DNAs were completely eradicated in 4 patients. Single-cell RNA-sequencing analysis showed that HLH syndrome was associated with hyperactive monocytes/macrophages and ineffective CD8 T cells with a defective activation program. Nivolumab treatment expanded programmed death protein-1‚Äìpositive T cells and restored the expression of HLH-associated degranulation and costimulatory genes in CD8 T cells. Our data suggest that nivolumab, as a monotherapy, provides a potential cure for r/r EBV-HLH, most likely by restoring a defective anti-EBV response.">

  
  <link rel="alternate" hreflang="en-us" href="https://shawnxpan.github.io/publication/2020_blood_paper/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    
      <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.14.0/css/all.min.css" integrity="sha256-FMvZuGapsJLjouA6k7Eo2lusoAX9i0ShlWFG6qt7SLc=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.1.2/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.1.2/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.css" integrity="sha256-SHMGCYmST46SoyGgo4YR/9AlK1vf3ff84Aq9yK4hdqM=" crossorigin="anonymous">
    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
    
      
      
      <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
    
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  




  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu8c40fb6acfd7a23e1c872bb3abf1a97c_23013_32x32_fill_lanczos_center_3.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu8c40fb6acfd7a23e1c872bb3abf1a97c_23013_192x192_fill_lanczos_center_3.png">

  <link rel="canonical" href="https://shawnxpan.github.io/publication/2020_blood_paper/">

  
  
  
  
  
  
  
    
  
  
  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="og:site_name" content="Shawn (Xiangyu) Pan">
  <meta property="og:url" content="https://shawnxpan.github.io/publication/2020_blood_paper/">
  <meta property="og:title" content="Nivolumab treatment of relapsed/refractory Epstein-Barr virus‚Äìassociated hemophagocytic lymphohistiocytosis in adults | Shawn (Xiangyu) Pan">
  <meta property="og:description" content="Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a life-threatening hyperinflammatory syndrome triggered by EBV infection. It often becomes relapsed or refractory (r/r), given that etoposide-based regimens cannot effectively clear the virus. r/r EBV-HLH is invariably lethal in adults without allogeneic hematopoietic stem cell transplantation. Here, we performed a retrospective analysis of 7 r/r EBV-HLH patients who were treated with nivolumab on a compassionate-use basis at West China Hospital. All 7 patients tolerated the treatment and 6 responded to it. Five of them achieved and remained in clinical complete remission with a median follow-up of 16 months (range, 11.4-18.9 months). Importantly, both plasma and cellular EBV-DNAs were completely eradicated in 4 patients. Single-cell RNA-sequencing analysis showed that HLH syndrome was associated with hyperactive monocytes/macrophages and ineffective CD8 T cells with a defective activation program. Nivolumab treatment expanded programmed death protein-1‚Äìpositive T cells and restored the expression of HLH-associated degranulation and costimulatory genes in CD8 T cells. Our data suggest that nivolumab, as a monotherapy, provides a potential cure for r/r EBV-HLH, most likely by restoring a defective anti-EBV response."><meta property="og:image" content="https://shawnxpan.github.io/publication/2020_blood_paper/featured.jpg">
  <meta property="twitter:image" content="https://shawnxpan.github.io/publication/2020_blood_paper/featured.jpg"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2020-05-04T13:15:44&#43;00:00">
    
    <meta property="article:modified_time" content="2020-03-01T00:00:00&#43;00:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://shawnxpan.github.io/publication/2020_blood_paper/"
  },
  "headline": "Nivolumab treatment of relapsed/refractory Epstein-Barr virus‚Äìassociated hemophagocytic lymphohistiocytosis in adults",
  
  "image": [
    "https://shawnxpan.github.io/publication/2020_blood_paper/featured.jpg"
  ],
  
  "datePublished": "2020-05-04T13:15:44Z",
  "dateModified": "2020-03-01T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Pengpeng Liu"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Shawn (Xiangyu) Pan",
    "logo": {
      "@type": "ImageObject",
      "url": "https://shawnxpan.github.io/images/icon_hu8c40fb6acfd7a23e1c872bb3abf1a97c_23013_192x192_fill_lanczos_center_3.png"
    }
  },
  "description": "Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a life-threatening hyperinflammatory syndrome triggered by EBV infection. It often becomes relapsed or refractory (r/r), given that etoposide-based regimens cannot effectively clear the virus. r/r EBV-HLH is invariably lethal in adults without allogeneic hematopoietic stem cell transplantation. Here, we performed a retrospective analysis of 7 r/r EBV-HLH patients who were treated with nivolumab on a compassionate-use basis at West China Hospital. All 7 patients tolerated the treatment and 6 responded to it. Five of them achieved and remained in clinical complete remission with a median follow-up of 16 months (range, 11.4-18.9 months). Importantly, both plasma and cellular EBV-DNAs were completely eradicated in 4 patients. Single-cell RNA-sequencing analysis showed that HLH syndrome was associated with hyperactive monocytes/macrophages and ineffective CD8 T cells with a defective activation program. Nivolumab treatment expanded programmed death protein-1‚Äìpositive T cells and restored the expression of HLH-associated degranulation and costimulatory genes in CD8 T cells. Our data suggest that nivolumab, as a monotherapy, provides a potential cure for r/r EBV-HLH, most likely by restoring a defective anti-EBV response."
}
</script>

  

  


  


  





  <title>Nivolumab treatment of relapsed/refractory Epstein-Barr virus‚Äìassociated hemophagocytic lymphohistiocytosis in adults | Shawn (Xiangyu) Pan</title>

</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class=" ">

  
  
  
    <script>const isSiteThemeDark = false;</script>
  
  
  <script src="/js/load-theme.js"></script>

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  












<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">Shawn (Xiangyu) Pan</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">Shawn (Xiangyu) Pan</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#projects"><span>Projects</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#publications"><span>Publications</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#contact"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      
      <li class="nav-item dropdown theme-dropdown">
        <a href="#" class="nav-link js-theme-selector" data-toggle="dropdown" aria-haspopup="true">
          <i class="fas fa-palette" aria-hidden="true"></i>
        </a>
        <div class="dropdown-menu">
          <a href="#" class="dropdown-item js-set-theme-light">
            <span>Light</span>
          </a>
          <a href="#" class="dropdown-item js-set-theme-dark">
            <span>Dark</span>
          </a>
          <a href="#" class="dropdown-item js-set-theme-auto">
            <span>Automatic</span>
          </a>
        </div>
      </li>
      

      

    </ul>

  </div>
</nav>



  <div class="pub">

  




















  
  
    
  


<div class="article-container pt-3">
  <h1>Nivolumab treatment of relapsed/refractory Epstein-Barr virus‚Äìassociated hemophagocytic lymphohistiocytosis in adults</h1>

  

  


<div class="article-metadata">

  
  
  
  
  <div>
    

  
  <span >Pengpeng Liu</span><span title="Equal contribution" class="author-notes">(*)</span>, <span >Xiangyu PanüòÅ</span><span title="Equal contribution" class="author-notes">(*)</span>, <span >Chong Chen, Ting Niu, Xiao Shuai, Jian Wang, Xuelan Chen, Jiazhuo Liu, Yong Guo, Liping Xie, Yu Wu, Yu Liu, Ting Liu</span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    March 2020
  </span>
  

  

  

  
  
  

  
  

</div>

  








  




  



<div class="btn-links mb-3">
  
  








  



<a class="btn btn-outline-primary my-1 mr-1" href="/publication/2020_blood_paper/2020_blood_paper.pdf" target="_blank" rel="noopener">
  PDF
</a>



<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/publication/2020_blood_paper/cite.bib">
  Cite
</button>


  
  
    
  
<a class="btn btn-outline-primary my-1 mr-1" href="https://github.com/pangxueyu233/Nivolumab-treatment-for-r-r-EBV-HLH" target="_blank" rel="noopener">
  Code
</a>


  
  
    
  
<a class="btn btn-outline-primary my-1 mr-1" href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138504" target="_blank" rel="noopener">
  Dataset
</a>











<a class="btn btn-outline-primary my-1 mr-1" href="https://doi.org/10.1038/s43018-022-00361-6" target="_blank" rel="noopener">
  DOI
</a>


  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary my-1 mr-1" href="https://ashpublications.org/blood/article/135/11/826/430074/Nivolumab-treatment-of-relapsed-refractory-Epstein" target="_blank" rel="noopener">
    
    Paper link
  </a>


</div>


</div>


<div class="article-header article-container featured-image-wrapper mt-4 mb-4" style="max-width: 720px; max-height: 539px;">
  <div style="position: relative">
    <img src="/publication/2020_blood_paper/featured_huba178ed00d7f60a3f887b7c7a5decf5b_8661956_720x0_resize_q90_lanczos.jpg" alt="" class="featured-image">
    
  </div>
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a life-threatening hyperinflammatory syndrome triggered by EBV infection. It often becomes relapsed or refractory (r/r), given that etoposide-based regimens cannot effectively clear the virus. r/r EBV-HLH is invariably lethal in adults without allogeneic hematopoietic stem cell transplantation. Here, we performed a retrospective analysis of 7 r/r EBV-HLH patients who were treated with nivolumab on a compassionate-use basis at West China Hospital. All 7 patients tolerated the treatment and 6 responded to it. Five of them achieved and remained in clinical complete remission with a median follow-up of 16 months (range, 11.4-18.9 months). Importantly, both plasma and cellular EBV-DNAs were completely eradicated in 4 patients. Single-cell RNA-sequencing analysis showed that HLH syndrome was associated with hyperactive monocytes/macrophages and ineffective CD8 T cells with a defective activation program. Nivolumab treatment expanded programmed death protein-1‚Äìpositive T cells and restored the expression of HLH-associated degranulation and costimulatory genes in CD8 T cells. Our data suggest that nivolumab, as a monotherapy, provides a potential cure for r/r EBV-HLH, most likely by restoring a defective anti-EBV response.</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>Blood</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"><p><b>Data availability</b>
The scRNA-seq data reported in this article have been deposited in the Gene Expression Omnibus database (accession number GSE138504).</br></p>
<p><b>Code availability</b>
Code used in this study is available on 
<a href="https://github.com/pangxueyu233/Nivolumab-treatment-for-r-r-EBV-HLH" target="_blank" rel="noopener">Github</a>.</p>
</div>

    






<div class="article-tags">
  
  <a class="badge badge-light" href="/tag/immunotherapy/">Immunotherapy</a>
  
  <a class="badge badge-light" href="/tag/hlh/">HLH</a>
  
  <a class="badge badge-light" href="/tag/relapse/">Relapse</a>
  
  <a class="badge badge-light" href="/tag/blood-disease/">Blood disease</a>
  
</div>



<div class="share-box" aria-hidden="true">
  <ul class="share">
    
  </ul>
</div>












  
    
    





  


  
    
    





  


  
    
    





  


  












  
  
  <div class="article-widget content-widget-hr">
    <h3>Related</h3>
    <ul>
      
      <li><a href="/project/immunotherapy/">Immunotherapy</a></li>
      
      <li><a href="/publication/2019_sttt_paper/">Epigenetic drug library screening identified an LSD1 inhibitor to target UTX-deficient cells for differentiation therapy</a></li>
      
      <li><a href="/publication/2022_jco_paper/">Striking effect of low-dose radiotherapy combined with PD-1 blockade on small cell lung cancer in mice and refractory patients (Achilles Study)</a></li>
      
      <li><a href="/publication/2021_cd_paper/">An Epigenetic Mechanism Underlying Chromosome 17p Deletion-Driven Tumorigenesis</a></li>
      
    </ul>
  </div>
  





  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.5.1/jquery.min.js" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/instant.page/5.1.0/instantpage.min.js" integrity="sha512-1+qUtKoh9XZW7j+6LhRMAyOrgSQKenQ4mluTR+cvxXjP1Z54RxZuzstR/H9kgPXQsVB8IW7DMDFUJpzLjvhGSQ==" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.1.2/highlight.min.js" integrity="sha512-7t8APmYpzEsZP7CYoA7RfMPV9Bb+PJHa9x2WiUnDXZx3XHveuyWUtvNOexhkierl5flZ3tr92dP1mMS+SGlD+A==" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.1.2/languages/r.min.js"></script>
        
      

    

    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.js" integrity="sha256-EErZamuLefUnbMBQbsEqu1USa+btR2oIlCpBJbyD4/g=" crossorigin="anonymous"></script>
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks",
        'slides' : "Slides"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.e2a1d664304232420550a13741e5d7ea.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      <a href="/privacy/">Privacy Policy</a>
    
    
       &middot; 
      <a href="/terms/">Terms</a>
    
  </p>
  

  <p class="powered-by">
    
  </p>

  
  






  <p class="powered-by">
    
    Copyright by Shawn.X.Pan
    

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
